|
Pembrolizumab with or without chemotherapy versus chemotherapy alone for patients with PD-L1–positive advanced gastric or gastroesophageal junction adenocarcinoma: Update from the phase 3 KEYNOTE-062 trial. |
|
|
Consulting or Advisory Role - Amgen; Array BioPharma; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Five Prime Therapeutics; Ipsen; Lilly; Macrogenics; Merck; Merck KGaA; Novartis; QED Therapeutics |
Research Funding - Five Prime Therapeutics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Plexxikon (Inst) |
Travel, Accommodations, Expenses - Bayer; Lilly; Merck |
|
|
Honoraria - Bristol-Myers Squibb; Takeda |
Consulting or Advisory Role - Abbvie; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; GlaxoSmithKline; Janssen; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda |
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Mediscience Planning (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst) |
|
|
Consulting or Advisory Role - Array BioPharma; Astellas Pharma; AstraZeneca; Bayer; Biocartis; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; GlaxoSmithKline; Halozyme; Incyte; Lilly; Merck KGaA; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche; SERVIER; Sirtex Medical; Taiho Pharmaceutical |
Research Funding - amgen (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Ipsen (Inst); Lilly (Inst); Merck (Inst); Merck KGaA (Inst); Novartis (Inst); Roche (Inst); SERVIER (Inst) |
|
|
No Relationships to Disclose |
|
|
Honoraria - Boryung; Ono Pharmaceutical |
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Daiichi Sankyo; ISU ABXIS |
Research Funding - ABL Bio (Inst); ALX Oncology (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); BeiGene (Inst); Bolt Biotherapeutics (Inst); Daiichi Sankyo (Inst); Five Prime Therapeutics (Inst); GC Pharma (Inst); InventisBio (Inst); Leap Therapeutics (Inst); LSK BioPharma (Inst); Macrogenics (Inst); MedPacto (Inst); Merck KGaA (Inst); MSD (Inst); Oncologie (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Pharmacyclics (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Trishula Therapeutics (Inst); Y-BIOLOGICS (Inst); Zymeworks (Inst) |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca; MSD; Roche |
Speakers' Bureau - Bayer; Bristol-Myers Squibb; MERCK |
Research Funding - Bristol-Myers Squibb (Inst); Novartis (Inst) |
Travel, Accommodations, Expenses - Roche |
|
|
Consulting or Advisory Role - Amgen; Beigene; Bristol-Myers Squibb; Celltrion; Gloria Biosciences; Lilly; Merck Serono; MSD; Quintiles; Taiho Pharmaceutical; Zymeworks |
Speakers' Bureau - Foundation medicine; Lilly; Merck Serono |
Research Funding - Amgen (Inst); Beigene (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); Taiho Pharmaceutical (Inst); Zymeworks (Inst) |
|
|
Consulting or Advisory Role - Mirati Therapeutics; Oncologie |
Research Funding - AstraZeneca; Lilly; Merck Sharp & Dohme |
|
Hugo Raul Castro-Salguero |
Speakers' Bureau - Pfizer; Roche |
|
Travel, Accommodations, Expenses - Roche |
|
|
Honoraria - BMS; BMS; Servier |
Consulting or Advisory Role - BMS; SERVIER |
|
Travel, Accommodations, Expenses - Ipsen; SERVIER; SERVIER |
|
|
Honoraria - Amgen; Bayer; Bristol-Myers Squibb; MSD; Roche; SERVIER |
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Lilly; MSD; Roche; SERVIER |
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); MSD (Inst) |
Travel, Accommodations, Expenses - MSD |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; MSD; Roche; Sanofi |
|
|
Honoraria - Bayer; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Merck; MSD; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha |
Research Funding - Daiichi Sankyo (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst) |
|
|
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Coherus Biosciences; Daiichi Sankyo; Foundation Medicine; Geneos; Lilly; Macrogenics; Merck; Novartis; Ono Pharmaceutical; Roche; Silverback Therapeutics; Turning Point Therapeutics |
Speakers' Bureau - Bristol Myers Squibb; Merck |
Research Funding - Brooklyn Immunotherapeutics (Inst); Merck (Inst); Novonco Therapeutics (Inst) |
Travel, Accommodations, Expenses - Amgen; Foundation Medicine; Macrogenics; Merck |
Other Relationship - Yiviva |
|
|
|
Stock and Other Ownership Interests - Merck |
|
|
|
Stock and Other Ownership Interests - Merck |
|
|
|
|
Stock and Other Ownership Interests - Merck |
|
|
Consulting or Advisory Role - Array BioPharma; AstraZeneca; Avvinity; Bayer; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; F. Hoffmann LaRoche; Genentech; HalioDx; Hutchison MediPharma; Ikena Oncology; IQvia; Lilly; Menarini; Merck Serono; Merus; Mirati Therapeutics; MSD; Neophore; Novartis; Ona Therapeutics; Orion Biotechnology; Peptomyc; Pfizer; Pierre Fabre; Samsung Bioepis; Sanofi; Scandion Oncology; Seagen; Servier; Taiho Pharmaceutical; Tessa Therapeutics; TheraMyc |
Other Relationship - Imedex; Medscape; MJH Life Sciences; Peerview; Physicans' Education Resource |